Wed, 12th Sep 2018 17:37
LONDON (Alliance News) - Drug development company Proteome Sciences PLC said Non-Executive Director Martin Diggle purchased 601,582 shares at a price of 3.60 pence per share on Tuesday.
Following this GBP21,657 transaction, Diggle now holds 59.3 million shares in Proteome, reflecting a 20% stake in the company.
Shares in Proteome closed trading down 5.0% at 3.63 pence on Wednesday.
Proteome Sciences PLC - London-based protein-focused drug development services provider - Proteome tells annual general meeting on Thursday it is "con...
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.
(Alliance News) - Proteome Sciences PLC on Friday said it won a contract from an unnamed US biopharmaceutical company to use Proteome's mass spectrome...
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.
(Sharecast News) - Contract proteomics service Proteome Sciences has secured a contract win from a US biopharmaceutical company using the company's ma...
Proteome (PRM)